Il martedì 6 febbraio 2024 alle ore 10:09:26 CET, daniela <daniela@autismo33.it> ha scritto:

Il 2024-02-05 19:21 Colla, Carlo ha scritto:

> Buonasera,

> Cosa ne dite dell’integratore palmitoiletanolamide (Pea) e sue

> applicazioni/effetti per l’autismo ? Qualcuno ne ha già sentito

> parlare ?

> Grazie mille

> Carlo

Nel 2021 è uscita una review che si puo’ leggere integralmente in rete

Colizzi M, Bortoletto R, Costa R, Zoccante L. Palmitoylethanolamide and

Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic

Review of Human and Animal Evidence. Nutrients. 2021 Apr 18;13(4):1346.

doi: 10.3390/nu13041346. PMID: 33919499; PMCID: PMC8073263.

https://www.mdpi.com/2072-6643/13/4/1346

Copio dall’articolo quanto segue

“ Palmitoylethanolamide (PEA) is a naturally occurring saturated

N-acylethanolamine that has proven to be effective in controlling

inflammation, depression, epilepsy, and pain, possibly through a

neuroprotective role against glutamate toxicity. ….

Limited research suggests that PEA supplementation reduces overall

autism severity by improving language and social and nonsocial

behaviors. Potential neurobiological underpinnings include modulation of

immune response, neuroinflammation, neurotrophy, apoptosis,

neurogenesis, neuroplasticity, neurodegeneration, mitochondrial

function, and microbiota activity, possibly through peroxisome

proliferator-activated receptor-α (PPAR-α) activation”

Ci sono buone premesse per fare delle sperimentazioni nel campo dello

spettro autistico.

Una sperimentazione sta partendo all’Università di Udine a cura di Marco

Colizzi

"The Supplementation Therapy in Autism and Response to Treatment Study

(START)

December 15, 2023 updated by: University of Udine

The Supplementation Therapy in Autism and Response to Treatment (START)

Study"

https://ichgcp.net/clinical-trials-registry/NCT06187090

Copio dal sito quanto segue

"Through this study, we wish to evaluate: the ability of PEA to

alleviate symptoms of psychic distress (i.e., anxiety and/or depression)

in Level 1 autistic adults; the safety and tolerability of sustained

intake of PEA in Level 1 autistic adults; and the biological basis of

PEA functioning…...

Volunteers who express an interest in the study and are identified as

having Level 1 autistic individuals with comorbid anxiety and/or

depressive symptoms by their clinical teams will be approached by study

researchers and given a patient information sheet. Those who agree to

take part in the study will be invited for a screening visit…….

As the present study was designed to assess the effect of PEA on

mentally fragile conditions with interference in the global functioning

of autistic individuals, we will focus on subjects with severity level

1, more affected by depressive and anxious symptoms than autistic

subjects with higher levels of impairment, requiring a prioritisation of

these manifestations compared to core symptoms”

La sperimentazione è ancora in fase di reclutamento per cui chi ha le

caratteristiche richieste dalla sperimentazione (adulti con autismo di

livello 1 con associati sintomi di ansia e/o depressione ) potrebbe

candidarsi a partecipare rivolgendosi a marco.colizzi@uniud.it o

bortoletto.riccardo@spes.uniud.it

Daniela Mariani Cerati

_______________________________________________

Lista di discussione autismo-biologia

autismo-biologia@autismo33.it

Autismo-biologia e' una lista di discussione promossa dall' A.P.R.I., Associazione Cimadori per la ricerca italiana sulla sindrome di Down, l'autismo e il danno cerebrale.

www.apriautismo.it

Per cancellarsi inviare un messaggio a: valerio.mezzogori@autismo33.it